The Full Wiki

Tropisetron: Wikis

  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Tropisetron
Systematic (IUPAC) name
(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 1methyl-indole-3-carboxylate
Identifiers
CAS number 89565-68-4
ATC code A04AA03
PubChem 72165
Chemical data
Formula C 17H20N2O2  
Mol. mass 284.353 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability ~60–80%
Protein binding 71%
Metabolism Hepatic (CYP3A4, CYP1A2, CYP2D6)
Half life 6–8 hours
Excretion Renal, Fecal
Therapeutic considerations
Pregnancy cat. X(AU)
Legal status Prescription Only (S4) (AU) POM (UK)
Routes Oral, IV

Tropisetron (INN) is a serotonin 5-HT3 receptor antagonist used mainly as an antiemetic to treat nausea and vomiting following chemotherapy, although it has been used experimentally as an analgesic in cases of fibromyalgia.[1] The drug is available in a 5 mg oral preparation or in 2 mg intravenous form. It is marketed by Novartis in Europe, Australia, New Zealand, Japan, South Korea and the Philippines as Navoban, but is not available in the U.S. It is also available from Novell Pharmaceutical Laboratories and marketed in several ASIAN countries as Setrovel

Contents

Pharmacology

Tropisetron acts as both a selective 5-HT3 receptor antagonist and α7-nicotinic receptor agonist.[2][3]

Adverse effects

Tropisetron is a well-tolerated drug with few side effects. Headache, constipation, and dizziness are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drug's use. It is broken down by the hepatic cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system.

See also

  • 5-HT3 receptor antagonist: Drug discovery and development

References

  1. ^ Muller, W.; T. Stratz (2004). "Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron". Scand J Rheumatic Suppl. 119: 44–48. PMID 15515413. http://www.hubmed.org/fulltext.cgi?uids=15515413. Retrieved 2007-05-17.  
  2. ^ Macor JE, Gurley D, Lanthorn T, Loch J, Mack RA, Mullen G, Tran O, Wright N, Gordon JC (February 2001). "The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist". Bioorganic & Medicinal Chemistry Letters 11 (3): 319–21. doi:10.1016/S0960-894X(00)00670-3. PMID 11212100. http://linkinghub.elsevier.com/retrieve/pii/S0960894X00006703.  
  3. ^ Cui R, Suemaru K, Li B, Kohnomi S, Araki H (May 2009). "Tropisetron attenuates naloxone-induced place aversion in single-dose morphine-treated rats: role of alpha7 nicotinic receptors". European Journal of Pharmacology 609 (1-3): 74–7. doi:10.1016/j.ejphar.2008.12.051. PMID 19374878.  

External links








Got something to say? Make a comment.
Your name
Your email address
Message